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SUMMARY  
 
Somatostatin receptor type 2 (SSTR2) is the main pharmacological target to treat different 
neuroendocrine tumors, including pituitary GH-secreting adenomas. Nevertheless, a subset of 
acromegalic patients, i.e. patients with a GH-secreting tumor, is not fully controlled by the medical 
therapy, and the molecular mechanisms underlying the pharmacological resistance to somatostatin 
analogues (SSAs) are not completely understood. Recently, the cytoskeletal protein Filamin A 
(FLNA) has been implicated in the regulation of tumor responsiveness by modulating SSTR2 
expression and signaling.  
The aims of the present study were to explore the in vivo dynamics of FLNA-SSTR2 interactions at 
the plasma membrane and the involvement of FLNA in the modulation of SSTR2 distribution and 
mobility. To this purpose, single-molecule imaging experiments were performed at the Institute of 
Pharmacology and Toxicology, University of  Würzburg  (Würzburg, Germany), at Dr. Davide 
Calebiro's lab. We also wanted to evaluate the impact of FLNA-SSTR2 binding on ligand-induced 
SSTR2 clusters organization and internalization.  
First, the motion of freely diffusing SSTR2 particles was observed to slow down upon CHO cells 
exposure to 100nM BIM23120. The trajectories of SSTR2 particles were used to calculate their 
diffusion coefficient through mean square displacement (MSD) analysis. A significant increase in 
the SSTR2 fraction with diffusion coefficient values ≤ 0.05μm2*s-1 with was detected in stimulated 
cells compared to unstimulated cells (28,1% vs 14,4%, expressed as fraction of total particles, 
respectively, P < 0.05). The presence of the FLNA truncated mutant, that selectively prevents 
SSTR2-FLNA binding (FLNA 19-20), did not influence the SSTR2 agonist effect on receptor 
mobility. Such data were further confirmed in melanoma cell lines. Then, we described the nature 
of the interactions between SSTR2 particles and FLNA fibers as extremely dynamic and transient 
under resting condition, whereas they resulted long-lasting and more stable after BIM23120 
6 
 
treatment. Interestingly, when both FLNA and SSTR2 were expressed at single molecule level, 
FLNA-SSTR2 complexes formation was seen to occur preferentially along actin filaments, in 
stimulated cells only. Furthermore, when overexpressed and stimulated, SSTR2 was observed to 
undergo clusters formation, and FLNA-SSTR2 binding was required to preserve SSTR2 clusters 
alignment on actin structures as well as their colocalization with the clathrin coated pits marker AP-
2. In addition, quantitative analysis of the agonist-triggered SSTR2 internalization demonstrated a 
significant reduction of the internalization rate in the presence of FLNA 19-20 compared to 
negative control (FLNA 17-18), at all the tested time points (eg. 45,3% ± 1,4% internalization vs 
71,4% ± 3,1% in FLNA 19-20 vs FLNA 17-18 transfected cells after 30min stimulation with 100nM 
BIM23120, respectively, P < 0,001), accordingly with biotinylation results. 
In conclusion, the behavior of FLNA-SSTR2 interactions were characterized for the first time by 
means of a high spatio-temporal resolution strategy. Altogether these results support a crucial role 
of FLNA in the recruitment of ligand-activated receptors and in their anchorage to the cortical actin 
cytoskeleton with important consequences on the overall SSTR2 internalization process.  
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1. INTRODUCTION 
 
1.1 SOMATOSTATIN AND ITS RECEPTOR FAMILY 
1.1.1 Somatostatin structure   
Somatostatin (SS), or somatotropin release-inhibiting factor, is a small cyclic peptide widely 
expressed throughout the central nervous system (CNS) and in several peripheral tissues such as the 
peripheral nervous system, pancreas, gut, thyroid, retina and others. In humans, there exists only 
one gene encoding for SS, located on chromosome 3q28 . The first mRNA product is a 116 amino 
acids precursor termed prepro-SS; this larger polypeptide is then processed to pro-SS of 92 amino 
acids, and finally to SS-28 and SS-14, the two biologically active forms consisting of 14 and 28 
amino acids, respectively (Brazeau et al., 1973) (Fig. 1). SS-28 comprises SS-14 and a NH2-
terminal extension (Fig. 2) (Shen et al., 1982) and encountered for only the 20-30% of the SS 
expressed in the brain.  
 
Figure 1. Illustrative picture of the SS precursor. Pro-SS (92 amino acids), SS-28 (28 amino acids) and SS-14 (14 
amino acids) originate from the grater polypeptide prepro-SS. 
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Figure 2. Amino acid sequence of the active form SS-14. Amino acid residues, Phe7, Trp8, Lys9 e Thr10, crucial for SS 
biological functions, are depicted in orange.  
 
1.1.2 Biological actions of SS 
SS plays a variety of biological functions accordingly to its location. In the CNS, SS acts as a 
neurotransmitter with both stimulatory and inhibitory effects on cognitive functions and locomotor 
activity. In fact, alterations of the somatostatinergic transmission at this level, have been related to 
different neurologic disorders, such as Alzheimer disease (Grouselle et al., 1998), HIV-
encephalopathy (Fox et al., 1997), Huntington's disease (Beal et al., 1988), Parkinson's disease 
(Strittmatter et al., 1996), and temporal lobe epilepsy  (Strowbridge et al., 1992). 
SS has a broad range of actions, almost exclusively inhibitory, on endocrine and exocrine gland 
secretion. SS is a crucial inhibitor of GH (Brazeau et al., 1973; Bertherat et al., 1995), TSH (Siler et 
al., 1974), ACTH (Richardson & Schonbrunn, 1981; Batista et al., 2006), and PRL release (Vale et 
al., 1974) from the anterior pituitary. Although the main effect of SS is to prevent hormonal 
exocytosis, in vitro and in vivo experiments have shown suppression of GH and ACTH transcription 
through SSTR2 action, as well (Castillo et al., 2011; Ben-Shlomo et al., 2013).  
At the peripheral nervous system level, SS controls the gastrointestinal tract activity by blocking the 
release of several hormones: colecystochinin, gastric inhibitory peptide, gastrin, motilin, 
neurotensin and secretin (Sheratori el al., 1991). Moreover, SS regulates bowel motility and gastric 
emptying, smooth muscles contraction, and nutrient absorption from the intestine. SS also 
suppresses the exocrine secretory action of pancreas, inhibiting glucagon, insulin and pancreatic 
polypeptide release (Stark & Mentlein, 2002; Ludvigsen et al., 2007). In the kidney, SS blocks 
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renin secretion (Gomez-Pan et al., 1976) and ADH-mediated water absorption (Reid & Rose, 1977), 
and in the adrenal gland prevents angiotensin II-stimulated aldosterone release and decreases 
catecholamines levels induced by acetylcholine. 
SS plays other inhibitory effects on growth factors (IGF-1, EGF, PDGF) and cytokine release from 
immune cells (IL6, IFN-β/γ) (van Hagen et al., 1994). Other SS functions comprise 
vasoconstriction, antiproliferative actions in lymphocytes and inflammatory cells of the intestinal 
mucosa as well as in the cartilage and bone precursors. 
 
1.1.3 Somatostatin receptors (SSTRs) structure  
SS mediates its biological actions by binding to five subtypes of seven transmembrane domain G-
protein-coupled-receptors (GPCRs), termed SSTR1-5 (Bruns et al., 1994; Patel, 1999). The SSTR 
subtypes can be classified into two groups, based on structural properties and pharmacological 
profiles. The first group includes SSTR2, SSTR3 and SSTR5 while SSTR1 and SSTR4 belong to 
the second group. Although they all bind SS-14 and SS-28 with high affinity, they display different 
affinity to SS analogs (SSAs). In particular, SSTR1 and SSTR4 do not bind octreotide and 
lanreotide, whereas SSTR2, SSTR5 and SSTR3 show high, moderate and weak affinity, 
respectively (Olias et al., 2004). The SSTRs are encoded by five genes localized on different 
chromosomes and the gene products have 42-60% sequence homology within different species 
(Patel et al., 1995). All SSTRs do not present introns in their coding sequences with the exception 
of sstr2, which contains one intron, thus two variants originate in rodents from mRNA alternative 
splicing: the unspliced form (SSTR2A) and a shorter, spliced form (SSTR2B), with smaller 
cytoplasmic tail. The long form of SSTR2 is the only one expressed in humans (Reisine & Bell, 
1995; Patel, 1999). The protein structure of SSTRs comprise of 356 - 391 amino acids and show 
high sequence homology within transmembrane domains. In particular, the seventh domain contains 
the typical signal peptide (YANSCANPI/VLY) characteristic of this receptor family (Patel, 1999). 
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At the cytoplasmic side of the third transmembrane domain is located another conserved  motif, the 
"DRY motif" (Asp-Arg-Tyr), which is necessary for G-protein coupling and inhibitory signal 
transduction. As recently demonstrated, the substitution of D136 and R137 residues in the DRY 
motif of SSTR5 resulted in the loss of the receptor ability to generate SS-mediated intracellular 
responses (Peverelli et al., 2009). 
In contrast, SSTRs mostly differ in the N- and C- terminal sequence. Moreover, SSTRs present 
different N-linked glycosylation sites at the N-terminal, and a variable number of phosphorylation 
sites for protein kinase A, protein kinase C and calmodulin kinase II at the C-terminal, second and 
third intracellular loops (Patel et al., 1995). 
 
1.1.4 SSTRs expression in the pituitary 
All five SSTR subtypes are expressed in fetal and normal pituitary, whereas SSTR4 is almost 
undetected in the adult gland (Reubi et al., 2001; Neto et al., 2009; Ben-Shlomo & Melmed, 2010). 
The long variant of SSTR2 is the only form expressed in the human pituitary, whilst truncated 
SSTR5 variants have been detected in rodents as well as in humans, in normal and tumoral pituitary 
samples (Duran-Prado et al., 2009; Córdoba-Chacón et al., 2010). Binding studies revealed that the 
SSTR subtypes predominantly expressed in GH-secreting adenomas are SSTR2 and SSTR5 
(expressed in more than 95% and 85% of tumors, respectively), followed by SSTR3 and SSTR1, 
both expressed in more than 40%; and finally SSTR4, which has rarely been found (Nielsen et al., 
2001; Tabaoda et al., 2007). Due to its most abundant expression, SSTR2 has been 
pharmacologically targeted with SSAs to treat acromegaly. The following part of this chapeter will 
then focused on SSTR2, in particular in terms of signaling, internalization properties and new 
discovered molecular mechanisms underlying SSAs pharmacological resistance in patients 
harbouring GH-secreting adenomas. 
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1.1.5 SSTR2-mediated signal transduction 
SS binding to SSTR2 leads to the activation of complex G-protein mediated signaling pathways, 
reflecting the pleiotropic effects of these receptor (Rens-Domiano &  Reisine, 1992; Moller et al., 
2003). G proteins are heterotrimeric molecules consisting of α, β and γ subunits. The α subunit 
determines the inhibitory or stimulatory nature of the G protein functional activity and contains the 
sites for GTP/GDP exchange. To date, 20 distinct α subunits have been cloned based on their 
structural homology and functions, and they have been divided in 4 groups: Gsα, Giα, Gqα, G12α. 
After ligand binding, a conformational change in the SSTR2 structure occurs, and the α subunit of 
Gi and Gq proteins are specifically recruited. The most characterized effects determined by Gi 
protein activation involve adenylyl cyclase activity inhibition, with resulting decrease in 
intracellular cAMP levels, and the modulation of ion channels (Patel et al., 1994). In fact, SSTR2 is 
directly coupled to potassium (K+) channels, whose activation determines plasma membrane 
hyperpolarization. SSTR2 can modulate K+ currents also in indirect manners, through the activation 
of phospholipase A2 and subsequent production of arachidonic acid, whose metabolites activate K+ 
channels, or through the stimulation of phospholipase C (PLC) signaling pathway (Meyerhof, 
1998). These events together with the closure of voltage-sensitive Ca2+ channels, reduce calcium 
(Ca2+) influx and intracellular Ca2+ level, causing an impairment in the mobility of secretory 
vesicles, and the reduction of GH secretion in the pituitary (Ben-Shlomo & Melmed, 2010).  
SSTRs control on cell proliferation is mediated by the stimulation of phosphotyrosine phosphatase 
(PTP) or mitogen-activated protein kinases (MAPK) activity (Ben-Shlomo & Melmed, 2010; Pan et 
al., 1992). Regarding SSTR2, its activation results in the coupling with PTP activation pathway 
involving the cytosolic Src homology 2 (SH2) domain, SHP1 (PTPN6), and SHP2 (PTPN11) and 
the membrane-anchored PTPη (DEP1) (Lopez et al., 1997). This, in turn, leads to growth factors 
kinases dephosphorylation, and the inhibition of mitogenic stimuli (Pages et al., 1999; Ferjoux et 
al., 2003), whereas SHP1-mediated nitric oxide synthase (NOS) dephosphorylation increases cGMP 
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levels and blocks cell proliferation (Bocca et al., 2000; Luque et al., 2005). SSTR2 negatively 
modulates the phosphatidylinositide-3-kinase (PI3K) target Akt (Bousquet et al., 2006) and inhibits 
ERK 1/2 activity with resulting ctitostatic effects (Sellers et al., 2000). Instead, cytostatic actions of 
SSTR5 seem to be PTP-independent but coupled to the PLC inhibitory pathway (Buscail et al., 
1995). Moreover, SSTR5 inhibits the activity of several MAPKs: Ras (Cattaneo et al., 1999), Raf-1 
(Cattaneo et al., 1996), c-fos (Cordelier et al., 1997) and ERK1/2 (Buscail et al. 1995, Peverelli et 
al., 2009). Both SSTR2 and SSTR5 activation up-regulates the cell cycle inhibitors p27Kip1 and 
p21Cip1 (Florio et al., 2001) which prevent the formation of the cyclin-dependent kinase (CDK) 
complexes, with consequent cell cycle arrest at the G1/S transition phase, as also reported in GH-
secreting pituitary adenomas (Ben-Shlomo & Melmed, 2010). 
SSTR2 and SSTR3 are the only SSTR subtypes that may initiate pro-apoptotic pathways. SSTR3-
induced cell apoptosis involves p53 accumulation (Sharma et al., 1996), whereas SST2 was rather 
found to act through different mechanisms involving the down-regulation of mitochondrial Bcl-2 
protein expression, and the up-regulation of the death receptors belongings to the TNF family 
(Teijeiro et al., 2002; Guillermet et al., 2003). In vitro experiments in tumoral cells from GH-
secreting pituitary adenomas demonstrated that the SSTR2-mediated cytotoxic effects comprise the 
induction of the enzymatic activity of caspase-3 and the increase of cleaved cytokeratin (CK) 18 
levels (Ferrante et al., 2006). Furthermore, in NIH-3T3 cells, SSTR2 was able to enhance the 
transcriptional activity of NF-kB and decrease JNK phosphorylation, causing cell apoptosis 
(Guillermet-Guiber et al., 2007). 
A schematic representation of the main intracellular SSTR2-mediated signaling cascades are 
depicted in figure 3. 
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Figure 3. Schematic representation of the most important SSTR2-mediated intracellular pathways in GH-secreting 
cells. After SS binding, Gi proteins are activated and act to reduce adenylyl cyclase activity with consequent decrease in 
cAMP levels; this together with the modulation of ion channels, reduces the intracellular Ca2+ concentration to block 
GH release. Antiproliferative actions of SSTR2 include the activation of PTP, the inhibition of the MAPK, and the up-
regulation of p27Kip1 to arrest cell cycle in phase G1. SSTR2-dependent cytotoxic actions are mediated by the 
modulation of the expression of pro-apoptotic proteins. 
 
1.1.6 Desensitization and internalization properties of SSTR2 
The GPCR signaling cascade terminates when GTP/GDP exchange occurs on the α subunit of the G 
protein and GPCR kinases (GRKs) phosphorylate specific acceptor sites on the receptor. These 
phosphorylation events, followed by arrestins recruitment, support receptor desensitization by 
sterically disrupting GPCRs/G protein coupling (Kohout & Lefkowitz, 2003; Luttrell & Lefkowitz, 
2002) thus preventing receptors from responding to further stimulation.  
Experimental observations allowed to better characterize the molecular mechanisms involved in the 
regulation of SSTR2 desenstitization and internalization (Fig. 4). After few minutes oh hormone 
binding, several serine and threonine residues in the C-terminal tail of the human SSTR2 termed 
Ser341, Ser343, Thr353, Thr354, Thr356 and Thr359, become phosphorylated, (Nagel et al., 2011; 
Lehmann et al., 2014). GRK2 and GRK3 have been identified as major players in the agonist-
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dependent SSTR2 phosphorylation, while PKA and PKC do not seem to be required (Hipkin et al., 
2000; Pöll et al., 2010). Both nonvisual arrestins, β-arrestin-1 and β-arrestin-2, translocate to the 
plasma membrane where they bind to the phosphorylated receptor (Tulipano et al., 2004).  β-
arrestins have two sensor sites important for receptor interaction: a phosphate sensor that recognizes 
receptor-attached phosphates or negatively charged amino acids, and an activation sensor that binds 
receptor elements that undergo conformational modification upon activation (Gurevich et al., 2006). 
In order to mediate SSTR2 endocytosis, β-arrestins act as scaffold proteins for components of the 
endocytic machinery, such as clathrin, adaptor protein 2 (AP2) and phosphoinositides. Accordingly 
to the classification proposed by Oakley and co-workers, based on the agonist-induced arrestin-
receptor binding properties, SSTR2 belongs to class B receptors (Oakley et al., 2000; Oakley et al., 
2001). In fact, SSTR2 displays similar affinity of interaction for both β-arrestin-1 and 2, and it 
stably interacts with them. This thigh receptor-arrestin association allows the complex to 
internalize, via clathrin coated pits (Koenig et al., 1998), into endosomal vesicles as an unit (Oakley 
et al., 2001).  
The internalized pool of receptors is then targeted to a perinuclear area resembling the Trans Golgi 
network (TGN) (Liu et al., 2005; Kao et al., 2011). After removal of ligand, most of the internalized 
receptor is rapidly dephosphorylated (Ghosh & Schonbrunn et al., 2011), and recycled to the plasma 
membrane (Tulipano et al., 2004) in contrast to what would be expected from a class B receptor. 
Finally, evidences from the literature showed that SSTR2 does not undergo any detectable 
lysosomal/proteosomal-induced degradation, since neither changes in SSTR2 ubiquitination level 
nor decrease of receptor expression have been reported even under prolonged stimulation protocols 
(Tulipano et al., 2004; Lesche et al., 2009; Peverelli et al., 2014).  
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Figure 4. Agonist-mediated SSTR2 internalization scheme, from Treppiedi et al., 2016. Upon agonist binding SSTR2 
activation results in the recruitment of Gi/o proteins (1) and the induction of biological responses (2). GRK-mediated 
phosphorylation of Ser and Thr residues located at the C-tail of SSTR2 terminates the signaling cascade. (3). β-
Arrestin-1/2 bind to the phosphorylated receptor and sterically prevent its interaction with Gi/o proteins, thus 
determining SSTR2 desensitization (4). The complex SSTR2-β-arrestin is targeted to specific plasma membrane areas 
where clathrin and AP2 cooperate to assemble clathrin coated vesicles (5). Receptor and β-arrestin internalize together 
into early endosomes (6). β-arrestin dissociates from SSTR2 after receptor dephosphorylation that is in turn directed to 
the recycling pathway (7). SSTR2 reaches the cell surface where it can sustain another cycle of stimulation (8).  
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1.2 GROWTH HORMONE-SECRETING PITUITARY ADENOMAS 
1.2.1 Growth hormone  
Growth hormone (GH) is a 191 amino acid single chain protein released by anterior pituitary 
somatotroph cells. GH secretion occurs in pulsatile bursts, especially at night, with extremely low 
or undetectable levels occurring in the nadir between pulses, and is governed by secretory factors 
such as GHRH (growth hormone releasing hormone) and ghrelin, and by the inhibitory 
hypothalamic SS. Both these stimulatory and inhibitory factors are subjected to higher influences 
within the brain as well as to peripheral signals, therefore the overall secretion of GH can vary 
widely under different physiological conditions such as growth, fasting, stress and exercise 
(Frohman et al., 1992). The biological effects of GH are mediated directly through the GH receptor 
and include the control of skeletal growth, the regulation of glucose levels, protein and lipid 
metabolism. Moreover, one of the major protein induced by GH is represented by the insulin like 
growth factor1 (IGF-1), which primarily origins from the liver and acts to reduce insulin action and 
stimulate lipolysis, eventually exerting a negative feedback on GH release (Clemmons, 2004). 
 
1.2.2 Acromegaly: epidemiology and aetiology 
The pathological excessive secretion of GH, and consequently IGF-1, is associated with a rare but 
severe endocrine disorder known as acromegaly. Acromegaly occurs with an approximate incidence 
of 3-4 new cases per million of population per year with an estimated prevalence of 60 per million 
(Holdaway & Rajasoorya, 1999).  
In more than 95% of cases the GH hypersecretion is due to a benign monoclonal pituitary adenoma 
which develops from the somatotroph cells that normally produce GH in the pituitary (Melmed et 
al., 1983). These somatotrophinomas are pure in 60% of cases, mixed GH- and prolactin (PRL)-
secreting adenomas in 25% of cases, whereas very rarely they can co-secrete TSH or ACTH 
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(Bassetti et al., 1986; Socin et al., 2003).  Pituitary carcinomas are extremely rare (less than 20 
cases published in the literature) (Pernicone et al., 1997). Infrequently acromegaly is caused by 
ectopic secretion of GHRH from a peripheral neuroendocrine tumor (Thorner et al., 1984), or from 
abnormal hypothalamic GHRH secretion (Asa et al., 1984). About 5% of cases are associated with 
familial syndromes, most commonly multiple endocrine neoplasia type 1 (MEN1) syndrome, but 
also McCune Albright syndrome, familial acromegaly, Carney’s syndrome and Familial Isolated 
Pituitary Adenoma (FIPA) (Horvath & Stratakis, 2008).  
Both genders are equally affected and the diagnosis is typically made in adults aged 40 – 60 years. 
However, due to the insidious nature of onset of symptoms and slow progression there is usually a 
considerable delay (in the range of 4-10 years) in the establishment of the correct diagnosis. 
Younger patients often present a more aggressive disease related to more rapidly growing 
adenomas. Very rarely the disorder begins during childhood, thus resulting in gigantism.  
 
1.2.3 Clinical description: symptoms and signs 
In more than 70% of cases, GH secreting pituitary adenomas are large tumors (macroadenoma, ≥ 10 
mm in diameter) which may present with local mass symptoms such as headache, visual field 
deficit or cranial nerve palsies, while microadenomas (< 10 mm in diameter) are less frequent. 
Defects of other anterior pituitary hormones secretion may also occur when the lesion increases in 
size. In fact, hypogonadism, presenting as decreased libido, infertility or oligo/amenorrhoea is a 
common finding at presentation and this may be due to both gonadotrophin deficiency as well as to 
hyperprolactinaemia, stalk compression or coexistent excessive secretion of prolactin (PRL), 
respectively (Greenman et al., 1995; Kaltsas et al., 1999). Patients with established acromegaly 
present a characteristic change in appearance comprising coarsening of the facial features: the nose 
is widened and thickened, the cheekbones are obvious, the forehead bulges, the lips are thick and 
the facial lines are marked. Mandibular overgrowth with prognathism, maxillary widening, 
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interdental separation and jaw malocclusion are typical signs of the disease as well as the 
enlargement of the hands and feet as reported in figure 5. 
 
Figure 5. Some of the most evident clinical features of acromegalic patients: prognatism, enlargment of hands, 
interdental separation and jaw malocclusion. The patient gave his consent to the use of these pictures. 
 
Generalised organomegaly is also commonly stated to occur in acromegaly (Molitch, 1992;). 
Accelerated degenerative changes particularly of the weight-bearing joints are a frequent 
occurrence leading to degenerative arthropathy (Stavrou & Kleinberg, 2001). Hypertrophy of the 
soft tissues of the upper airway and macroglossia that often result in obstructive sleep apnoea, 
represent other classical clinical manifestations, together with the reduced lung capacity that can 
turn in pulmonary complications (Grunstein et al., 1991). Acromegaly is also associated with 
decrease in fat mass, increase in lean body mass and muscle hypertrophy (Katznelson, 2009). 
Moreover, lipid metabolism alterations lead to the development of insulin resistance, hypertension 
and cardiomyopathy (Gama et al., 1997; Giustina et al, 2003), therefore, besides a considerable 
impairment of quality of life, uncontrolled patients have an increase in morbidity with an overall 
mortality at least two-fold that of the general population due to cardiovascular and cerebrovascular 
complications (Holdaway et al., 2004). In addition, it has become evident that patients with 
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acromegaly have an increased risk of developing neoplasia, particularly colon cancer (Renehan et 
al., 2003), whether the susceptibility to other malignancies remains controversial (Melmed, 2001).  
 
1.2.4 Diagnosis: biochemical and radiological assessment 
The diagnosis of acromegaly is made using a combination of clinical examination of the typical 
disfigurement of the patient and analysis of biochemical parameters. Patients with acromegaly have 
typically elevated serum GH concentrations, that are not suppressed to a level < 0.4 ng/ml following 
an oral glucose load (oral glucose tolerance test, OGTT) (Ben-Shlomo & Shlomo, 2008). 
Measurement of serum GHRH may be performed in the rare patients in whom a non-pituitary 
aetiology is suspected. A skull x-ray represents a quick and easy preliminary assessment for the 
confirmation of the disease, even though more detailed information regarding the presence and size 
of a pituitary mass requires a computed tomography or, better, an MRI contrast enhanced scan, as 
shown in figure 6. Neuro-ophthalmological assessment is obligatory in all cases of acromegaly and 
assessment of the integrity of the other pituitary hormones needs to be performed by a combination 
of the appropriate basal and dynamic tests.  
 
Figure 6. MRI image indicating a GH-secreting pituitary macroadenoma. 
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1.2.5 Management and treatment 
The clinical aims for acromegaly are: to relieve symptoms, to reduce the volume of the pituitary 
tumor, to prevent the recurrence, and to improve long-term morbidity and mortality. The control of 
the disease is achieved when GH concentration returns below 2.5 μg/l or GH nadir after 75g OGGT 
less than 1.0 μg/l and IGF-I level returns in the normal range adjusted for age and gender (Giustina 
et al., 2000). A stepwise therapeutic approach using surgery and/or radiotherapy and/or medical 
treatment allows to satisfy these goals.  
Currently, trans-sphenoidal surgery is the initial treatment of choice for the majority of patients. 
With modern equipment and experienced surgeon, it is a safe procedure with a low complication 
rate and mortality of less than 0.5%. In the last decades, surgical techniques have included the use 
of intra-operative MRI (Fahlbusch et al., 2005) and intra-operative growth hormone measurement 
(Abe & Ludecke, 1999), while the development of endoscopic trans-sphenoidal surgery has been 
reported to offer several advantages in terms of superior tumor clearance, especially suprasellar 
extension, less surgical morbidity, fewer complications, and reduced post-operative discomfort 
(Frank et al., 2006). The major long-term complication associated with trans-sphenoidal surgery is 
worsening of anterior pituitary function and hypopituitarism (Sheaves et al., 1996). Others minor 
complications include diabetes insipidus, cerebral spinal fluid (CSF) rhinorrhoea and the syndrome 
of inappropriate antidiuretic hormone secretion (SIADH). Surgical outcome is carefully assessed at 
three months. When surgery fails to achieve a good disease control, or when surgery is impossible 
or contraindicated, patients are offered radiotherapy and/or pharmacological treatments.  
Radiotherapy in this setting is usually external and centered on the tumor; an average total dose of 
50 Gy is delivered in about twenty five daily sessions. Highly focused irradiation (radiosurgery, 
stereotactic radiotherapy, "gamma-knife", etc.) is now available in some centres, and causes less 
damage to neighbouring tissues. 10–15 after irradiation, a variable degree of anterior pituitary 
insufficiency has been reported in 80% to 100% of patients. Complications including radionecrosis 
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and optic neuropathy are now very rare. On the other hand, the risk of stroke may be increased, 
sometimes many years after radiotherapy (Brada et al., 1999).  
Regarding the medical therapy, three different types of drugs are currently available in the clinical 
practice: SSAs, GH antagonists and dopamine agonists. 
The potent antisecretory and antiproliferative properties of SSTR and the identification of the key 
molecular structural characteristics of SS, provided the basis for the development, in the mid- 
1980’s, of specific ligands which represented the real therapeutic advance for acromegaly. 
Octreotide (Sandostatin, Novartis, Basel, Switzerland), the 8 amino acid synthetic somatostatin 
analog, was the first compound to be marked (Bauer et al., 1982). This SSA showed a considerable 
increase of half-life compared to the native SS (approximately 90-seconds), and its administration 
subcutaneously in a thrice-daily regimen resulted in stable drug concentrations and maximal effects. 
GH concentration reduction was seen in more than 90% of patients, with approximately 50-60% 
achieving levels of less than 2 ng/ml and a normal serum IGF-1 level. Currently, octreotide is not 
used anymore for chronic treatment in acromegalic patients, since long lasting formulations of 
SSAs have become available. These formulations contain a biodegradable polylactide and 
polyglycolide polymers from which the active drug is released after intramuscular injection. There 
are three such preparations available, octreotide LAR (Sandostatin LAR, Novartis) which has high 
affinity for SSTR2 and moderate and weak affinity for SSTR5 and SSTR3 (McKeage et al., 2003), 
respectively, is given at a variable dose of 10 mg, 20 mg or 30 mg at recommended four weekly 
intervals; lanreotide (Somatuline Autogel, Ipsen Biotech, Paris, France), which acts as a selective 
agonist of SSTR2 and SSTR5, is given as a single dose of 60-120 mg every 28 days as a sub-
cutaneous depot formulation (Castinetti et al., 2009); and the recently licensed pasireotide LAR 
(SOM230) which displays increased affinity for SSTR5, but is also selective for SSTR2 and 
SSTR3, and shows enhanced binding to SSTR1 compared to octreotide (Bruns et al., 2002; Lewis 
et al., 2003).  
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Figure 7. Amino acid sequences of three somatostatin receptor ligands, octreotide, lanreotide and pasireotide. 
 
Another therapeutic approach to decrease GH level in acromegalic patients is represented by 
pegvisomant, the new genetically engineered growth hormone molecule that acts by binding 
peripheral GH receptors, preventing  receptor dimerization and subsequent signal transduction, and 
blocking IGF-I synthesis (Berryman et al., 2007). This GH receptor antagonist is the major advance 
in the treatment of acromegaly with several studies demonstrating its effectiveness and long-term 
efficacy (Trainer et al., 2000). However its role as first line option remains to be determined and to 
date it is mostly used for patients with proven resistance to long-term high-dose SSAs treatment 
after unsuccessful surgery and/or radiotherapy (Colao et al., 2006). The main drawbacks of 
pegvisomant are its daily injection requirement, and its high cost, thus it is not yet universally 
available. 
Dopamine agonists (DA), such as bromocriptine and cabergoline, are ergot-derived dopamine 
analogs selective for the dopamine receptor type 2 (DRD2). These compounds were used as the sole 
pharmacological treatment for acromegaly until the introduction of SSAs. Although approximately 
80% of patients showed a decrease in GH levels after treatment with bromocriptine, only about 10-
15% achieved a complete control (Wass et al., 1977). Furthermore, bromocriptine attenuated 
moderately the symptoms and the reduction in tumor size was insignificant. Cabergoline, instead, 
offered greater advantages and appeared to be more effective (Sandret et al., 2012), and it is 
currently used in combination with SSAs (Cozzi et al., 2004). 
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1.2.6 Resistance to SSAs  
According to published reports, about one third of patients receiving the medical therapy 
displays resistance to SSAs and fails to obtain a complete control of the disease (Ben-Shlomo 
& Melmed 2008; Melmed et al., 2009; Fleseriu, 2013). Resistance to SSAs can be defined as: 1) 
persistent basal GH excess associated to GH nadir greater than 1.0μg/liter after OGTT and 
IGF-I levels above the normal range adjusted for age and gender, known as the “biochemical 
resistance”; and 2) increase in tumor size or a tumor shrinkage less than 20% compared with 
baseline volume, known as the “tumor resistance” (Gola et al., 2006).  
The molecular mechanisms underlying the variable sensitivity of GH-secreting pituitary 
adenomas to SSAs have been extensively investigated over the past years, and three main 
hypotheses have been raised to explain this biological phenomenon: 
1. impairment or heterogeneity of SSTR within the tumors, or decrease density of the SSTR 
subtypes with higher affinity to SSAs;  
2. SSTRs gene mutations; 
3. post-receptor alterations. 
2.5.1 Alteration of SSTRs expression 
The first hypothesis is the most investigated and supported by good evidence showing a 
reduced density of SSTR, especially SSTR2 and/or SSTR5 in GH-secreting adenomas from 
resistant patients. A significant correlation between the absence of SSTR2 expression and the 
poor hormonal response to SSAs  has been reported in vivo (Plöckinger et al., 2008). 
Accordingly, Reubi and Landolt showed that a quantitative loss of SSTR accounted for the 
reduced sensitivity or resistance of a group of GH-secreting pituitary tumors in response to 
acute administration of somatostatin or octreotide (Reubi & Landolt, 1989). Moreover, SSTR2 
expression resulted positively correlated with SSAs response, at both mRNA and gene product 
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levels (Taboada et al., 2008). In addition, another independent study demonstrated the 
existence of a positive association between SSTR2 expression, at a protein level, and in vitro 
GH suppression or in vivo IGF-I control (Ferone et al., 2008). A recent study performed with 
monoclonal anti-SSTR2 antibody immunostaining of paraffin-embedded tissues predicted 
SSAs responsiveness in acromegalic patients (Brzana et al., 2013).  
However, such a loss of SSTR2, is not always found in resistant patients and cannot give an 
exhaustive explanation for the partial GH-suppressive effects of SSAs. Therefore, some studies 
focused on SSTR5, the other SSTR subtype widely expressed in GH-secreting tumors, 
correlating the resistance of a group of GH-secreting pituitary adenomas to SSAs with an 
absent or reduced density of SSTR5 (Gadhela et al., 2013). Moreover, there are observations 
highlighting the synergic effect on GH secretion resulting from the activation of SSTR2 and 
SSTR5 (Tulipano et al., 2001), and evidence showing enhanced functionality of SSTR2/SSTR5 
heterodimers (Rocheville et al., 2000; Grant M; et al., 2008). The altered heterogeneity of 
SSTRs pattern within the tumor may be related to the pharmacological resistance to SSAs. In 
this regard, a study performed on a series of resistant GH-secreting adenomas revealed the 
lack of a homogeneous distribution of the SSTRs with high affinity for SSA (Reubi et al., 1987). 
This led to the hypothesis that a weak sensitivity to SSAs might be linked to the outgrowth of 
tumor cell clones still expressing SSTRs, but those subtypes for which SSAs display low 
affinity, thus explaining the basis of the secondary development of resistance. Altogether 
these works support the thesis of a key role of SSTR2 and SSTR5 expression in the 
development of a variable sensitivity to SSAs.  
2.5.2 Mutations in SSTR genes 
As reported in the literature, gene mutations leading to a loss of function in SSTR were rarely 
found in patients bearing GH secreting adenomas, suggesting that this hypothesis cannot 
actually be at the basis of pharmacological resistance to SSAs (Petersenn et al., 2000; Corbetta 
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et al., 2001). To date, the only known germ line mutation (R240W) in the SSTR5 gene was 
found by Ballarè and colleagues in a patient with a GH secreting adenoma resistant to SSAs 
treatment (Ballarè et al., 2001): this missense mutation resulted in reduced inhibitory effect 
of SS on GH release and cell growth. In vitro experiments in GH3 cells showed that the mutant 
R240W receptor maintained its ability to decrease adenylyl cyclase activity but lost the 
inhibitory action on GH secretion as a consequence of a lack of coupling with GoA protein but not 
with the other G proteins activated by wild type SSTR5, for example, Gi1, i2, i3 and GoB (Peverelli et 
al, 2009; Peverelli et al., 2013). Moreover, in CHO cells transfected with the mutated receptor, 
the antiproliferative effect of SS resulted reverted, as demonstrated by an increase in the 
MAPK activity compared with wild-type cells (Peverelli et al., 2009) 
Several studies evaluated the presence of polymorphisms in SSTR2 and SSTR5 genes in a large 
series of patients with acromegaly, eventually attempting to correlate them to the sensitivity 
to SSAs. However, none of the described polymorphic variants in SSTR2 and SSTR5 (t80c, c-
57g, and a-83g in SSTR2, t-461c and c1004t in SSTR5) seem to play a major role in determining 
SSAs resistance (Filopanti et al., 2005; Lania et al., 2008). Conversely, the truncated variants of 
SSTR5 (SSTR5TMD4) has been correlated with resistance to octreotide and tumor invasive 
behavior in SSTR2 expressing GH-secreting adenomas (Durán-Prado et al., 2010; Luque et al., 
2015). The dominant-negative effect of SSTR5TMD4 on SSTR2-mediated signaling has been 
demonstrated by different approaches, and SSTR2-SSTR5TMD4 interaction was found 
responsible for the reduced SSTR2 responsiveness to SS (Durán-Prado et al., 2012) likely by 
altering the normal SSTR2 trafficking to the plasma membrane (Durán-Prado et al., 2009). 
2.5.3 Post-receptor alterations  
In attempt to understand the molecular mechanisms underlying the pharmacological resistance to 
SSAs, many studies focused on post-receptor alterations involving the intracellular signaling 
molecules directly activated by SSTRs. The decreased sensitivity of SSTRs to SSAs may be in 
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fact related to receptor uncoupling with the transduction system, and pharmacological 
resistance may affect distinct SS-induced intracellular pathways, as documented in rare cases 
of non-responder acromegalic patients in which the resistance selectively involved the 
antisecretory effects or the antiproliferative actions of SSAs (Casarini  et al., 2006; Resmini et 
al., 2007).  
Few data are available regarding G proteins alterations as possible determinants of  pituitary 
tumor resistance to SSAs (Ballarè et al., 1997). However, it is worth nothing that about 30-
40% of acromegalic patients carry somatic activating mutations in the gene coding for the α 
subunit of Gs proteins (GNAS, also known as gsp oncogene). This mutation is associated with 
elevated basal adenylyl cyclase activity, poor responsiveness to GHRH, and higher sensitivity 
to SSAs, a characteristic that still lacks of an explanation since no increase in SSTRs expression 
have been reported in these adonomas (Spada et al., 1990; Barlier et al., 1999). 
Genetic alterations in aryl hydrocarbon receptor interacting protein (AIP) seem to play a role 
in SS-resistance of non familial acromegalic patients. AIP is considered a tumor-suppressor 
gene that, acting through ZAC, is able to induce tumor shrinkage (Chahal et al., 2012). In 
addition, AIP inactivation has been demonstrated to affect Gi signaling and induce pituitary 
tumorigenesis (Tuominen  et al., 2015). Indeed, genetic analysis on 50 sporadic GH-secreting 
adenomas classified as not responder to SSAs revealed the presence of a low prevalence of 
germline mutations in AIP gene (Oriola et al., 2012). 
The antiproliferative effects of SS are in part mediated by the MAPK pathway. Alteration in 
this signaling cascade, in particular regarding the expression level of Raf kinase inhibitory 
protein (RKIP), has been to found to affect the responsiveness of GH-secreting adenomas to 
SSAs (Fougner et al., 2008), as well. 
Lately, it has been hypothesized that alterations in β-arrestins recruitment or in the arrestins 
expression levels could play a role in SSTR desensitization, internalization and trafficking, 
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thus modulating  the response to SSTR-targeting drugs in GH-secreting pituitary adenomas. 
Peverelli and colleagues demonstrated that the previously mentioned naturally occurring 
missense mutation R240W, located in the third intracellular loop of SSTR5, strongly impaired 
receptor agonist-induced phosphorylation, arrestin interaction, and receptor internalization 
(Ballarè et al., 2001; Peverelli et al., 2008), with important consequences on receptor signaling 
(Peverelli et al., 2009; Peverelli et al., 2013). Recent findings from another work negatively 
correlated β-arrestin-1 mRNA expression with the reduction of GH levels in acromegalic 
patients after acute octreotide stimulation (Gatto et al., 2013). In addition, low β-arrestin-1 
and 2 mRNA expression and high GRK2 and SSTR2 mRNA levels have been detected in 
adenoma samples deriving from patients in which GH secretion was well inhibited by 
octreotide administration with respect to the resistant group (Gatto et al., 2016). Therefore, 
altered β-arrestins-SSTR2 interaction might eventually affect the rate of SSTR2 recycling and 
availability at the cell surface, thus determining a reduced in vivo responsiveness to SSAs. 
Filamin A (FLNA), a recently discovered modulator of SSTR2 expression and signaling in GH-
secreting adenomas, further validated the hypothesis of  post-receptor alterations as possible 
causes for the pharmacological resistance to SSAs. The role of FLNA will be discussed in detail 
in the following chapter of the present thesis. 
 
 
 
 
 
 
28 
 
 
 
 
1.3 FILAMIN A  
1.3.1 FLNA structure  
The mammalian Filamins belong to a family of large actin binding proteins comprises of three 
members: FLNA, B and C, with a high homology in their coding sequence (van der Flier & 
Sonnenberg A, 2001). Specifically, FLNA, mapping to Xq28, is the most expressed isoform in 
human adults and was the first actin binding protein discovered in non muscle cells (Hartwig and 
Stossel, 1975). Human genetic diseases associated with FLNA mutations have been described, such 
as the X-chromosome-linked brain malformation known as periventricular nodular heterotopia 
(PVNH), otopalatodigital syndrome (OPD), frontometaphyseal dysplasia (FMD), and Melnick 
Needles syndrome (MNS) (Robertson et al., 2003). 
FLNA structure is characterized by the self-association of two monomers of 280 kDa each. Each 
subunit has an actin-binding domain (ABD) localized at the N-terminal containing two calponin-
homology domains CH1 and CH2, followed by 24 immunoglobulin (Ig)-like repeats of about 96 
amino acid residues fold into antiparallel β-sheets. The first calpain-sensitive hinge region (H1) 
separates the repeats in 2 rod domains (Rod-1 and Rod-2). Rod-1 (repeats 1–15)  contains a 
secondary actin binding domain with lower affinity, while Rod-2 (repeats 16–23) has a more 
globular structure and function as interface for intracellular factors interaction (Nakamura et al., 
2011). The second hinge region divides Rod-2 from the repeat 24, at the C-terminal, which 
represents the region of dimerization that confers to FLNA a V-shaped flexible arrangement. A 
schematic representation of FLNA is depicted in the figure 8. 
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Figure 8. Illustrative image of FLNA structure. The main actin binding domain is located at the N-terminal, followed 
by 24 repeats Ig-like, divided by the first hinge region in two rod domains: Rod 1 (repeats 1-15) and Rod-2 (repeats 16-
23). The second hinge region separates the repeat 23 from the repeat 24. The monomers self-association site is located 
at the C-terminal and FLNA dimerization promotes orthogonal junctions of F-actin. 
 
 
1.3.2 FLNA biological functions  
The biological functions of FLNA relies on its proteic structure. Infact, thanks to its extended 
filamentous structure, the main FLNA action is to cross-link F-actin into perpendicular branchings 
and form a cytoskeleton network in order to maintain the physiological cell shape. Moreover, 
FLNA orchestrates the engineering of the actin cytoskeleton in response to extracellular chemotattic 
stimuli. Another FLNA function is to physically anchor transmembrane proteins (GPCRs, ion 
channels, integrins) to the cortical actin structures (Stossel et al., 2001), thus regulating their 
localization and stability at the plasma membrane. FLNA also acts as a scaffold protein for signal 
transduction, by interacting with several cytosolic molecules such as kinases and transcription 
factors (Nakamura et al., 2011). Some of FLNA binding proteins are indicated in the figure below 
(figure 9). 
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Figure 9. Schematic representation of FLNA interaction sites for partner proteins. 
 
Furthermore, several data support the idea of FLNA as a key modulator of internalization and 
intracellular trafficking of transmembrane proteins. To this regard, FLNA has been recently 
demonstrated to actively coordinate DRD2 targeting to the cell surface in pituitary tumoral 
lactotrophs cells (Peverelli et al., 2012), promote DRD3 internalization (Lin et al., 2001; Cho et al., 
2007) and direct surface HCN1 channels into endosomes in hippocampal neurons (Noam et al., 
2014). In addition, FLNA and caveolin-1 interaction resulted involved in the clustering and lateral 
mobility of caveolae at the plasma membrane and responsible for the enhanced caveolae 
internalization in endothelial cells (Muriel et al., 2011). Cytokine receptor 2B (CCR2B) requires 
FLNA for clathrin coated pits formation and subsequent endocytosis (Minsaas et al., 2010). Further 
evidence showed that agonist-induced μ-opioid receptor internalization and intracellular trafficking 
are both positively supported by FLNA (Onoprishvili et al., 2003), whereas FLNA protects the 
calcitonin receptor (Seck et al., 2003), the calcium sensing receptor (Zhang & Breitwieser, 2005) 
and the cystic fibrosis transmembrane conductance regulator and the high-affinity IgG receptor 
FcRI (Thelin et al., 2007; Beekman et al., 2008) against degradation. Altogether these results 
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pointed out the pleiotropic role of FLNA in the organization of cellular compartments and directing 
protein traffic. All FLNA actions are regulated by phosphorylation events, proteolysis, mechanical 
forces, and multimerization with different partners.  
 
1.3.3 Role of FLNA in the regulation of SSTR2 and impact on pharmacological resistance of 
GH-secreting adenomas  
A recent published work showed that FLNA directly binds SSTR2. This FLNA-SSTR2 interaction 
was detected by surface plasmon resonance and involves the first intracellular loop of SSTR2 and 
FLNA repeats 19–20. 
FLNA coupling to SSTR2 resulted crucial to sustain the SSTR2 antiproliferative effects in 
pancreatic tumor cells BON and in melanoma cell lines. Moreover, the authors demonstrated that 
FLNA stabilizes SSTR2 at the plasma membrane after ligand binding and regulates its endocyotosis 
rate (Najib et al., 2012).  
In a following study, FLNA has been identified as a possible candidate for the determination of the 
pharmacological resistance to SSAs of GH-secreting pituitary adenomas (Peverelli et al., 2014). 
The more relevant results of the study concerned the functional role of FLNA in the regulation of 
SSTR2 signaling in tumoral somatotrophs as well as in a rat pituitary GH-secreting cell line GH3. 
In fact, FLNA supported SSTR2 effects on cell proliferation inhibition and on cell apoptosis 
induction. Moreover, in downregulation experiments, FLNA resulted crucial to prevent SSTR2 
lysosomal degradation, thus stabilizing the receptor expression. This evidence has been 
demonstrated in GH3 cells overexpressing a FLNA dominant negative mutant that selectively 
avoids FLNA-SSTR2 interaction (FLNA repeats 19–20), with SSTR2 expression resulting 
significantly reduced after 72 h of agonist treatment. Furthermore, a FLNA fragment containing the 
repeats 21-24 of FLNA was used to generate a dominant negative for FLNA scaffold functions, 
since these repeats represent the region of FLNA mainly involved in the interaction with 
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intracellular partner proteins. Indeed, the overexpression of this truncated mutant strongly impaired 
the cytotoxic and cytostatic effects of SSTR2 in GH3 cells, suggesting that the FLNA scaffold 
function is necessary for the assembly of signal transduction complexes SSTR2-activated. Finally, 
although no correlation between FLNA and SSTR2 have been detected at the protein level and no 
effect on receptor localization have been observed after FLNA silencing in GH secreting adenomas 
samples, altogether these data support the hypothesis that low levels of FLNA might correlate with 
the poor response to SSAs in GH-secreting pituitary tumors still expressing SSTR2. 
Similar effects of FLNA on the regulation of DRD2 have been obtained in PRL-secreting pituitary 
adenomas, thus confirming the crucial role of this protein in modulating the responsiveness of 
different pituitary tumors to the medical therapy (Peverelli et al., 2012). Moreover, in a recent study 
Vitali and collegues also demonstrated that FLNA is essential for SSTR2 expression, signaling and 
internalization in pancreatic neuroendocrine tumors (P-NET) (Vitali et al., 2016).  
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2. AIM OF THE STUDY 
 
SSTR2 is one of the most expressed SSTR subtypes in GH-secreting pituitary adenomas and 
currently represents the main pharmacological target to treat acromegalic patients with somatostatin 
analogs (SSAs). However, the complete control of the disease is achieved in only two thirds of 
patients undergoing medical therapy, with a consistent subset of resistant cases. Recently, 
increasing attention has been focused on SSTR2-post receptoral alterations as possible molecular 
mechanisms underlying the biological phenomenon of drug resistance.  
In this contest, FLNA, a large cytoskeleton protein with scaffold functions, has been pointed out as 
a new modulator of agonist activated-SSTR2 response and stability at the plasma membrane in GH-
secreting cells. It is well known that cytoskeleton elements are able to mediate the formation of 
specialized domains at the plasma membrane, where cell surface receptors are assembled into 
functional units essential for the intracellular signaling transduction, and are involved in ligand-
promoted receptor endocytosis, eventually regulating the amount of active receptor. However, to 
date there are no data in the literature describing the dynamic of SSTR2/FLNA interaction at the 
plasma membrane in vivo.  
Therefore the aims of the present study were to get insights into the SSTR2 behavior at the cell 
surface before and after agonist stimulation, to evaluate the spatial arrangement of FLNA-SSTR2 
complexes and the possible involvement of FLNA in regulating SSTR2 mobility and agonist-
triggered clusters formation.  
One of the most useful ways to study the formation of protein complexes and the occurrence of 
protein-protein interactions at the cell surface is to monitor their movements. SSTR2/FLNA 
interactions were analyzed at single-molecule level by single-molecule imaging, a powerful tool for 
the characterization of dynamic processes with high spatial and temporal resolution.  
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Moreover, we aimed to characterize the impact of the disrupted SSTR2/FLNA interaction on the 
anchorage of SSTR2 pits to the actin cortical cytoskeleton, and on the overall SSTR2 internalization 
process. 
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3. MATERIALS AND METHODS 
 
3.1 Plasmids and Constructs 
Plasmid encoding human SSTR2 was kindly provided by Dr. Stefan Schulz (Institute of 
Pharmacology and Toxicology, Jena University Hospital, Friedrich-Schiller-University, Jena, 
Germany). SNAP-tagged SSTR2 construct was cloned by fusing the N-terminus of the wild-type 
receptor to the SNAP sequence into a pcDNA vector, where the SNAP tag is located directly after 
the FLAG sequence (Calebiro et al., 2013). SNAP-tag is a 20 kDa peptide derived from the enzyme 
O6-alkylguanine-DNA-alkyltransferase (AGT) that can be covalently labeled with synthetic dyes 
linked to benzylguanine (BG) allowing the visualization of the fused protein of interest.  
Plasmid CLIP-tagged FLNA was generated by replacing EGFP with CLIP-tag in the construct 
coding for FLNA-EGFP (Planagumà et al., 2012) kindly provided by Dr. Anna M. Aragay (Institut 
de Biologia Molecular de Barcelona, Spain), with CLIP-tag introduced in the first hinge region of 
the FLNA monomer. CLIP-tag is a further engineered peptide that can be efficiently labelled with 
benzylcytosine derivatives.  
FLNA truncated mutants constructs, containing the FLNA repeats 19-20 and 17-18 (FLNA 19-20, 
FLNA 17-18) used to prevent SSTR2/FLNA interaction and as a control, respectively, were 
previously described (Peverelli et al., 2014). Indeed, the repeats 19-20 of FLNA were demonstrated 
to interact with the first intracellular loop of SSTR2 in vitro (Najib et al., 2012). The N-terminus of 
these FLNA fragments were fused with the dsRed protein, allowing the monitoration of the 
transfection efficiency at a fluorescence microscope and resulting in a stabilized expression of the 
short peptides.   
Lifeact-GFP was used as a marker for the visualization of F-actin in living cells after transfection. 
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3.2 Cell Culture  
Chinese hamster ovary K1 (CHO-K1) cells were maintained in Dulbecco's modified Eagle's 
medium/nutrient mixture F-12 (DMEM/F12) supplemented with 10% (v/v) Fetal Bovine Serum 
(FBS), 100 U/ml penicillin and 100 µg streptomycin. Human melanoma cell line M2 (lacking 
expression of FLNA) and isogenic cell line A7 (stably expressing full-length FLNA) were kindly 
provided by Dr. Fumihiko Nakamura (Harvard Medical School, Boston, MA, USA) and cultured in 
α-minimal essential medium (MEM) supplemented with 8% (v/v) newborn calf serum (NBCS), 2% 
(v/v) FBS, and antibiotics. A7 cells were cultured in the presence of 500 μg/ml G418. Human 
Embryonic Kidney 293 (HEK293-AD) cells were grown in Dulbecco's modified Eagle's medium 
(DMEM) supplemented with 10% (v/v) FBS, 2mM glutamine, and antibiotics. Cells were 
maintained in a humidified atmosphere of 5% CO2 at 37 °C. 
 
3.3 cAMP Measurements  
To confirm the functional activity of SNAP-tagged SSTR2 in terms of cAMP inhibition ability, 
HEK293-AD cells were transiently cotransfected for 48 h with 1μg of the wild-type or SNAP-
tagged SSTR2 and 1 μg of the Epac1-camp sensor using the Effectene reagent (QIAgen, Hilden, 
Germany), according to the instructions of the manufacturer.  
The construct coding for the cAMP sensor comprises of a cAMP-binding domain, derived from the 
exchange protein directly activated by cAMP (Epac), flanked on each side by CFP either YFP. 
Forskolin-triggered intracellular cAMP levels were recorded before and after incubation with 
increasing concentration of the selective SSTR2 agonist BIM23120 (Ypsen, Milan, IT), by 
Fluorescence Resonance Energy Transfer (FRET) measurements, following the previously 
described protocol (Nikolaev et al., 2004). In our settings, the inhibition of cAMP accumulation 
SSTR2-mediated results in a reduced binding of cAMP molecules to the Epac1-camps determining  
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a conformational change so that the distance between the CFP and YFP decreases causing an 
increase of FRET ratio. Ratiometric FRET experiments were performed on a Zeiss Axiovert 200 
inverted microscope equipped a polychrome V light source a beam splitter and a CoolSNAP HQ 
CCD Camera. Graphpad Prism 5 software was used to plot in a logarithmic scale data from 10 cells 
for each group from three independent transfections. 
 
3.4 Single-Molecule and Total Internal Reflection Fluorescence Microscopy 
Single-molecule imaging is a strategy which combines the labelling of SNAP/CLIP-tagged proteins 
with small organic fluorophores and the use of a total internal reflection fluoresence (TIRF) 
microscope to unreveal their dynamics and heterogeneous behaviors on the surface of living cells. 
The low penetration depth (maximum ~200nm) obtained with TIRF microscopy allows to strongly 
reduce the background fluorescence and makes the technique particularly suited to study biological 
events occurring at the plasma membrane. An illustrative picture of the method is shown in figure 
10. 
 
Figure 10. Single-molecule imaging requires low expression levels of SNAP/CLIP tagged proteins labeled with small, 
bright organic dyes. The visualization of distinct particles at the plasma membrane of living cells is performed with a 
TIRF microscope. The concept of TIRF microscopy relies on the physical phenomenon of the total internal refraction 
light (TIR). TIR occurs when the incident angle of the excitation light beam at the coverslip is greater than the ‘critical 
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angle’ so that the light is totally reflected back towards the objective lens and a thin electromagnetic field, known as the 
evanescent field, is generated at the interface. Only fluorophores located at the cell surface can be excited and detected. 
 
 
For single-molecule experiments, CHO cells and melanoma cells were seeded on 24-mm clean 
glass coverslips at a density of 3 and 4,5 × 105 cells per well, respectively, in complete phenol-red-
free medium in order to minimize autofluorescence. Indeed, extensive coverslips cleaning is 
essential to reduce the background fluorescence. The procedure consists of two consecutive 
incubations with chloroform and 5M NaOH, respectively, in a bath sonicator for 1 h each. The day 
after plating, cells were transiently transfected with 2 μg of total amount of DNA and 4-6 μL of 
Lipofectamine 2000 transfection reagent (Invitrogen, Carlsbad, CA), according to the instructions 
of the manufacturer. Cells were analyzed 4–12 h after transfection to achieve low expression. CHO 
cells, M2 and A7 cells transfected with SNAP-tagged SSTR2 were labeled with 1 µM Alexa647-
BG (Alexafluor 647-SNAP Surface; New England Biolabs, UK). CHO cells also expressing CLIP–
tagged FLNA were labeled with 1 µM BC-TMR (CLIP-Cell TMR-Star; New England Biolabs, 
UK), as well. The labeling was performed in complete phenol-red–free medium for 20 min at 37 °C 
5% CO2. At the end of the incubation, cells were washed three times with complete phenol-red–free 
medium, each time followed by 5 min incubation at 37°C, and immediately imaged. These 
conditions resulted in optimized labeling of cell-surface SNAP-tagged receptors and intracellular 
CLIP-tagged FLNA particles. 
A custom total internal reflection fluorescence (TIRF) microscope (Eclipse Ti, Nikon) equipped 
with four EM-CCD cameras (iXon3+ DU897D-CSO, Andor), and a 100× oil-immersion objective 
(CFI Apo TIRF 100x/1.49, Nikon) was used. Cells were first searched and focused using bright 
field illumination, then a fine focus adjustment was performed switching to TIRF mode, always 
keeping the intensity of the laser power as low as possible (3% laser power). This procedure 
minimized photobleaching before image acquisition. Afterward, laser powers were set to 30% and 
image sequences (300–400 frames) were acquired with an exposure time of 30 ms, with an  interval 
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between frames of 61.9 ms. The penetration depth of the evanescent field was ∼110 nm. The 
microscope was equipped with an incubator and a temperature control unit (Tempcontrol 37-2 
digital, PeCon). Experiments were performed at 20.5 ± 0.3 °C. Only cells with less than 0.45 
receptor particle/μm2 were analyzed.   
 
3.5 MSD analysis  
Single-molecule movies were processed using the NIH ImageJ software as reported in the 
previuosly described protocol (Sungkaworn et al., 2014), and then subjected to the computational 
analysis for particle detection and tracking following a recently described u-track algorithm 
implemented in Matlab (The Math Works) (Jaqaman et al., 2008). The diffusion speed of receptor 
particles was calculated on the basis of their mean square displacement (MSD) as explained in the 
work of Calebiro and colleagues (Calebiro et al., 2013). 
 
3.6 Fluorescence Microscopy 
For fluorescence microscopy analysis, CHO cells were plated on 13-mm coverslips at a density of  
1,5 × 105 cells per well in p24 well plate and grown at 37°C for 18 h. Cells were then cotransfected 
with Lifeact-GFP, SNAP-tagged SSTR2 and FLNA 19-20/FLNA 17-18 using Lipofectamine 2000 
as transfection reagent and following the instructions of the manufacturer. Receptors were labeled 
24-48h after transfection and treated with saturating concentration (100nM) of BIM23120 up to 10 
min to observe receptor clusters, and for 15, 30, and 60 min to monitor receptor internalization, at 
37°C. Cells were then fixed with 4% paraformaldehyde for 10 min at room temperature, and 
washed several times in PBS (Thermofisher, Rockfor, IL). Coverslips were mounted on glass slides 
with ProLong Diamond Antifade mounting medium with 4',6-diamidino-2-phenylindole (DAPI) 
(Life Technologies, Carlsbad, CA) for fluorescence microscopy examination. Images acquisition 
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was performed using a Leica TCS SP2 laser scanning confocal microscope equipped with Ar 
488nm and HeNe 543nm lasers (Leica Microsystem, Deerfield, IL). For internalization 
experiments, about 8-12 equatorial confocal sections from cell bodies were sequentially collected to 
ensure a scan thickness of ∼ 500 nm and then images were processed with the NIH ImageJ software 
as subsequently described.  
 
3.7 Immunofluorescence  
CHO cells, transfected and treated as above described, were also used for immunofluorescence 
experiments. After fixation, cells were permeabilized with 0.3% Triton X-100 in PBS for 5 min and 
incubated with 10% FBS in PBS for 30 min to block unspecific sites. Cells were then incubated 
with a 1:250 dilution of anti AP-2 antibody (Thermofisher, Rockfor, IL) for 2 h at room 
temperature, washed 3 times with 0.05% Tween 20 in PBS and stained with Alexa Fluor 488 
conjugated secondary antibody (Thermofisher, Rockfor, IL) for 1 h at room temperature. Both 
primary and secondary antibodies were diluted in an antibody dilution buffer containing 1% BSA, 
0.3% Triton X-100 in PBS. After extensive washing, coverslips were mounted on glass slides and 
observed at the laser scanning confocal microscope for the analysis of SSTR2 - AP-2 
colocalization. 
 
3.8 Quantification of SSTR2 Internalization by Confocal Imaging 
SSTR2 internalization was first evaluated by confocal microscopy. This imaging approach allows to 
analyze the amount of internalized receptor after agonist stimulation in single cells. The 
fluorescence density mean (F) in two distinct regions corresponding to the plasma membrane and to 
the whole intracellular area were densitometrically determined in each cell. Mean membrane to 
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intracellular fluorescence ratio (fR) was then calculated as previously reported (Peverelli et al., 
2008) according to the following equation:  
fR = [F(membrane) - F(background)] / [F(total) - F(background)]. 
The NIH ImageJ program was used to analyze at least 30 cells for each group from three 
independent transfections, and the mean value ± SD expressed as % of basal was used for the graph.  
 
3.9 Quantitative Analysis of SSTR2 Internalization by Biotinylation Assay 
Cell surface-proteins biotinylation assay was used to biochemically determine the receptor 
internalization rate. CHO cells transiently expressing wild type-SSTR2 were washed three times 
with ice-cold PBS, followed by a 30 min incubation with 500 µg/ml cleavable EZ-Link sulfo-NHS-
SS-biotin (Thermofisher, Rockfor, IL) at 4 °C. Unreacted biotin was blocked and removed by three 
washes with cold Tris-buffered saline-10mM glycine. Biotinylated cells were incubated in 
prewarmed medium with or without 100 nM BIM23120 at 37 °C for 30 min, and then chilled on ice 
to stop SSTR2 endocytosis. Glutathione (Sigma-Aldrich, St. Louis, MO) was used to release the 
biotin label from proteins at the cell surface: cells were washed twice with cold glutathione strip 
buffer (50 mM glutathione, 75 mM NaCl, 75 mM NaOH, 10% FBS in H2O), at 4 °C for 20 min. 
Excess of glutathione was then quenched by 30 min iodoacetamide (Sigma-Aldrich, St. Louis, MO)  
incubation at 4 °C. 50 mM Iodoacetamide was dissolved in a proper buffer containing 1% BSA, in 
PBS, pH 7.4. Cells were lysed with 100 µl lysis buffer and 60 µg of total cellular protein was 
incubated with 1 μg of SSTR2 (yI-17) antibody (Santa Cruz Biotechnology, Santa Cruz, CA) over 
night at 4 °C on a rotating device, for immunoprecipitation. The resuspended volume of protein 
A/G Plus-Agarose (20 µl) was then added, and tubes were incubated for 3 h at 4 °C in rotation. 
After 5 washes with ice-cold PBS, the pellet was resuspended in 45 µl of Blue loading buffer for 
immunoblotting. Eluted proteins were resolved by SDS-PAGE under nonreducing conditions. To 
detect biotinylated proteins, 1:500 dilution of anti-biotin, horseradish peroxidase-linked antibody 
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was used (Cell Signaling Technology, Danvers, MA). The presence of equal amounts of receptor in 
the immunoprecipitates was confirmed by stripping and reprobing with anti-SSTR2 antibody 
(1:200) and antimouse secondary antibody covalently coupled to horseradish peroxidase (1:2000). 
The resulting bands were analyzed with the NIH ImageJ software. Experiments were repeated in 
triplicate.  
 
3.10 Statistical Analysis 
Data were analyzed by unpaired Student t test and, where indicated, with Mann-Whitney test (Prism 
5; GraphPad Software, San Diego, CA). The results are expressed as the mean ± SD or SEM and P 
< 0.05 was accepted as statistically significant. 
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4. RESULTS 
 
4.1 Single molecule visualization of SSTR2 and FLNA 
To directly observe SSTR2 and FLNA particles at the cell surface of living cells, we followed the 
procedure developed by Calebiro and collegues (Calebiro, et al., 2013). The functional activity of 
the SNAP-tagged receptor was confirmed by examining its ability to inhibit adenyl cyclase and 
reduce intracellular levels of cAMP (Fig. 1), whilst CLIP-tagged FLNA was validated for correct 
stress fibers organization and ability to colocalize with actin (Fig. 2A and B). 
 
Figure 1. Functional characterization of SNAP-tagged SSTR2 construct. HEK293AD cells were transfected with 
SNAP-tagged SSTR2 or wild-type receptor together with Epac1-camps. Cells were incubated with increasing 
concentration of SSTR2 selective ligand BIM23120 and FRET measurements were performed to evaluate receptor 
ability of inhibiting the cAMP-production forskolin-triggered. SNAP-tagged SSTR2 construct is functional, as shown 
by cAMP concentration-response dependencies, comparable to those observed in wild-type SSTR2 transfected cells. 
Data are means ± SEM of 10 cells from three different experiments.  
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Figure 2. Validation of CLIP-tagged FLNA construct. (A) TIRF images of CHO cells transfected with FLNA-EGFP 
and CLIP-tagged FLNA, respectively. At the plasma membrane, CLIP-tagged FLNA construct displays the correct cell 
organization in stress fibers, similar to FLNA-EGFP. (B) TIRF images of CHO cell cotransfected with CLIP-tagged 
FLNA (green) and Lifeact-GFP (red). The colocalization between CLIP-tagged FLNA and actin filaments was analyzed 
by NIH ImageJ and is shown in white, confirming the actin-binding property of the CLIP-tagged FLNA construct. Scale 
bars, 10µm. 
  
SNAP-tagged SSTR2 and CLIP-tagged FLNA were visualized in real time at the cell surface of 
CHO cells by TIRF microscopy (Fig. 3A, D). SSTR2 and FLNA particles detection (Fig. 3B, E) 
and tracking (Fig. 3C, F) was performed with the algorithm developed by Jaqaman and coworkers 
(Jaqaman K et al., 2008).  
 
    -     
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Figure 3. Single molecule visualization and tracking of individual SSTR2 and FLNA particles at the plasma 
membrane of living cells. CHO cells transfected with SNAP-tagged SSTR2 (A) or CLIP-tagged FLNA (D), labeled 
with Alexa647-BG and TMR-star dyes, respectively, and imaged by TIRF microscope. (B and E) Results of particle 
detection from images in A and D, respectively. (C and F) Representative images of particles tracking from detected 
particles in B and E, respectively; the current position (blue circle) and trajectory (blue spline) of each molecules are 
indicated. Scale bars, 10µm.  
 
4.2 SSTR2 slow down after agonist stimulation 
We evaluated the lateral mobility of functional SNAP-tagged SSTR2 particles at the plasma 
membrane in transfected CHO cells. Briefly, the individual SSTR2 particle coordinates over time 
were used to calculate their mean square displacement (MSD) and diffusion coefficient. Results 
from this analysis showed that under basal condition most receptors were freely diffusing  at the cell 
surface. Interestingly, 5-10 min exposure to 100nM of the selective SSTR2 agonist BIM23120 
slightly reduced SSTR2 diffusion speed (mean diffusion coefficient from 0,125µm2*s-1 to 
0,110µm2*s-1), but caused a statistically significant enrichment in the receptor fraction characterized 
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by a limited mobility (particles with diffusion coefficient ≤ 0.05µm2*s-1 = 28,1% in stimulated cells 
vs 14,4% in control cells, P < 0.05) (Fig. 4).  
 
Figure 4. Effect of the SSTR2 selective agonist on receptor lateral mobility. CHO cells were transfected with 
SNAP-tagged SSTR2, labeled with 1 μM Alexa647-BG and stimulated or not with 100nM of BIM23120 for 5-10 min 
before image acquisition with TIRF microscope. The trajectories of individual SSTR2 particles were used to generate 
the distributions of their diffusion coefficient of treated cells (red line) compared with nonstimulated cells (black line). 
100nM BIM23120 incubation slightly reduces SSTR2 mobility, but significantly increases the fraction of particles with 
diffusion coefficient values ≤ 0.05µm2*s-1.  For particles with diffusion coefficient values in the range 0.00µm2*s-1 -  
0.05µm2*s-1 the difference are statistically significant by Mann-Whitney test (P < 0.05). 
 
To test a possible involvement of FLNA in mediating the agonist effect on the SSTR2 motion at the 
plasma membrane, we calculated the distribution of SSTR2 diffusion coefficients in CHO cells 
transiently overexpressing SSTR2 and FLNA 19-20, the FLNA fragment that plays a dominant 
negative effect for the binding of SSTR2 to the endogenous FLNA. FLNA 17-18 was used as a 
control peptide. It has to be taken into account that CHO cells endogenously express FLNA (Najib 
et al., 2012) and that the FLNA residues involved in SSTR2 binding are conserved between human 
and hamster. The incubation in the presence of 100nM BIM23120 resulted in a reduced receptor 
speed in respect to the resting condition, in both FLNA 17-18 transfected cells (mean diffusion 
coefficients from 0,123µm2*s-1 to 0,101µm2*s-1) and FLNA 19-20 expressing cells (mean diffusion 
coefficients from 0,123µm2*s-1 to 0,110µm2*s-1). However, no significant differences in SSTR2 
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lateral mobility were found in the absence of FLNA-SSTR2 interaction with respect to both basal 
and stimulated FLNA 17-18 expressing cells (Fig. 5).  
 
Figure 5. Testing an involvement of FLNA in regulating SSTR2 motion. CHO cells cotransfected with SNAP-
tagged SSTR2 and FLNA 17-18 or FLNA 19-20 constructs, labeled with 1μM  Alexa647-BG and treated or not with 
100nM of BIM23120 for 5-10 min before image acquisition at TIRF microscope. Statistical analysis of the distributions 
of SSTR2 diffusion coefficients were performed with one-way ANOVA followed by Bonferroni’s multiple comparison 
test and did not show any significant differences between FLNA 19-20 expressing cells compared with both control 
unstimulated and stimulated cells. 
 
Similar results were obtained in human melanoma cell lines A7 (FLNA-expressing) and M2 
(FLNA-lacking). It has to be mentioned that under basal condition SSTR2 were slightly more 
mobile in M2 cells compared to A7 cells (mean diffusion coefficient = 0,148µm2*s-1 vs  
0,119µm2*s-1, in M2 vs A7 cell lines, respectively). Nevertheless, upon 100nM BIM23120 
treatment, SSTR2 slow down in both cell lines, meaning that the complete lack of FLNA does not 
affect the action of SSTR2 agonist on receptor speed (Fig. 6). 
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Figure 6. Evaluation of SSTR2 lateral mobility in A7 and M2 cell lines. A7 (FLNA-expressing)  and M2 (FLNA-
lacking) cell lines were transiently transfected with SNAP-tagged SSTR2 and labeled with 1μM Alexa647-BG dye. 
Image acquisitions were performed with TIRF microscope before and after 5-10 min of 100nM BIM23120 incubation. 
Upon stimulation, SSTR2 mean diffusion coefficient shifts from 0.119µm2*s-1 to 0.101 µm2*s-1 and from 0.148 µm2*s-1 
to 0.105µm2*s-1, in A7 and M2 cells respectively. There are no significant differences in SSTR2 lateral mobility in A7 
cells compared to both treated and untreated M2 cells. 
 
 
4.3 SSTR2 and FLNA undergo transient interactions which are increased by agonist 
stimulation and occur prevalently at actin fibers 
We then investigated the dynamic behaviour of SSTR2-FLNA interactions in living CHO cells. We 
overexpressed the full-length FLNA-EGFP in order to visualize FLNA arrangement in fibers, and 
expressed SSTR2 at single molecule level to be able to follow the movement of single receptors 
along FLNA structures. Extremely dynamic and transient interactions between SSTR2 and FLNA 
fibers were observed and recorded under resting condition, whereas after 100nM BIM23120 
treatment, SSTR2 was found to statically interact with FLNA structures, revealing a stronger 
affinity of binding between FLNA and ligand-activated receptors (Fig. 7).  
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Figure 7. Dynamic visualization of SSTR2-FLNA interactions by TIRF-M.  FLNA-EGFP (red) fibers and single 
molecules of SNAP-tagged SSTR2 (green) labelled with 1μM Alexa647-BG dye are expressed at the cell surface of 
cotransfected CHO cells. Representative frames of image sequences acquired by TIRF-M are here reported to 
characterize SSTR2-FLNA interactions occurred in real time, in both untreated and treated cells. The upper panel 
represents an example of dynamic interactions occurring between SSTR2-FLNA under resting condition: the arrows 
indicate two SSTR2 particles which transiently "touch" different side of the same FLNA filament (1) or get in contact 
with distinct FLNA fibers (2), respectively. The lower panel shows an example of static SSTR2-FLNA interactions 
resulted from 10 min stimulation with 100nM BIM23120: the arrows indicated agonist-activated receptors characterized 
by an absent or very limited mobility on FLNA fibers. 
 
Next, we investigated the role of the cortical actin cytoskeleton in organizing SSTR2-FLNA 
complexes at the plasma membrane. To this aim we cotransfected CHO cells with single molecule 
expression levels of both CLIP-tagged FLNA and SNAP-tagged SSTR2, while Lifeact-GFP was 
overexpressed to allow the visualization of F-actin. Very temporary and short FLNA-SSTR2 
interactions along actin filaments were observed under basal condition (Fig. 8), whilst in 100nM 
BIM23120 stimulated cells, static and long-lasting interactions between SSTR2 and FLNA particles 
were found to occur prevalently at actin fibers, suggesting an active role of the cortical actin 
network in spatially and temporally coordinating such SSTR2-FLNA complexes (Fig. 9).  
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Figure 8. Single-molecule visualization of SSTR2-FLNA complexes interaction with actin cytoskeleton under 
resting conditions. (A) First frame of a representative TIRF-M image sequence acquired in living CHO cell expressing 
single-molecule levels of SNAP-tagged SSTR2 (green) and CLIP-tagged FLNA (blue), labeled with Alexa647-BG and 
TMR-STAR dyes, respectively and overexpressing Lifeact-GFP (red). Scale bar 10μM. (B) Higher magnification of the 
detail of the image sequence in A. Example of two distinct particles of SSTR2 and FLNA showing a dynamic and 
transient colocalization along an actin filament. A merging event (white) is quickly followed after some frames by a 
splitting event.  
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Figure 9. Single-molecule visualization of SSTR2-FLNA complexes interaction with actin cytoskeleton after 
receptor stimulation. (A) First frame of a representative TIRF-M image sequence acquired in living CHO cell 
expressing single-molecule levels of SNAP-tagged SSTR2 (green) and CLIP-tagged FLNA (blue), labeled with 
Alexa647-BG and TMR-STAR dyes, respectively and overexpressing Lifeact-GFP (red). The acquisition was 
performed after 10 min of receptor stimulation with 100nM BIM23120 and the picture shows several whitish spots 
(arrows) indicating SSTR2-FLNA particles colocalizing with actin fibers. Scale bar 10μM. (B) Higher magnification of 
the detail of the image sequence in A. Example of two distinct particles of SSTR2 and FLNA forming a stable and long-
lasting complex localized on actin cytoskeleton. A merging event (white) lasts for several seconds until FLNA 
bleaching (last frame shown). 
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4.4 Disrupting SSTR2-FLNA interaction does not affect SSTR2 clustering formation but 
SSTR2 anchorage to actin cytoskeleton and organization in pits    
To characterize more in detail the role of the actin cytoskeleton in organizing SSTR2 distribution at 
the cell surface, we performed confocal imaging experiments in CHO cells transfected with SNAP-
tagged SSTR2 and Lifeact-GFP. Moreover, we overexpressed FLNA fragments to test the impact of 
the disrupted SSTR2-FLNA interaction on SSTR2 anchorage to actin structures. In absence of 
stimulation, SSTR2 resulted widely distributed at the plasma membrane in both control cells (cells 
cotransfected with Lifeact-GFP and FLNA 17-18, and cells expressing Lifeact-GFP, only) and in 
FLNA 19-20 expressing cells. After 10 min of SSTR2 agonist exposure, it was possible to 
appreciate a pattern of receptor clusters in all the tested conditions. Interestingly, the loss of FLNA-
SSTR2 binding, achieved by overexpressing FLNA 19-20, did not affect SSTR2 clusters formation 
but rather impaired SSTR2 clusters alignment along actin fibers, which was preserved in stimulated 
control cells (Fig. 10). In fact, in the presence of the FLNA dominant negative mutant 19-20 most of 
the receptor clusters were spatially off-centered from the F-actin. These findings highlighted the 
important role of FLNA as a physical link between SSTR2 complexes and the cortical actin 
cytoskeleton, and suggested a possible involvement of FLNA in the regulation of SSTR2 early 
endocytotic events. 
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Figure 10. FLNA-SSTR2 binding preserves receptor clusters arrangement along actin filaments. CHO cells were 
transiently cotransfected with Lifeact-GFP (red), SNAP-tagged SSTR2 (green) and where indicated, FLNA truncated 
mutants FLNA 19-20/17-18 (white, lower inset). After labeling, cells were incubated in presence or absence of 100nM 
BIM23120 for 10 min at 37 °C, then fixed in PFA 4% and mounted on coverslips for confocal microscopy analysis. The 
figures are representative sections of the plasma membrane and show the overall SSTR2 distribution and localization in 
respect to the actin cortical cytoskeleton. (Left panel) Under basal condition, SSTR2 results widely spread at cell 
surface in control cells and FLNA 19-20 expressing cells. (Right panel) After BIM23120 incubation, SSTR2 clusters 
occurrence is visible in all the tested conditions. (Upper inset) Higher magnification of SSTR2 clusters localization 
along actin structures, showing that FLNA-SSTR2 binding is required to spatially anchor SSTR2 clusters to the cortical 
cytoskeleton, as observed in FLNA 17-18 transfected cells and cells expressing Lifeact-GFP only, but in FLNA 19-20 
expressing cells. 
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To test this hypothesis, we first better defined the nature of the observed agonist-induced SSTR2 
clusters, by immunofluorescence experiments. CHO cells, previously transfected with SNAP-
tagged SSTR2 and FLNA truncated mutants, were immunostained for the adapting protein-2 (AP-
2), a well-recognized clathrin-mediated endocytosis marker, to investigate the presence of SSTR2 
clusters in clathrin-coated pits. As expected, after 5-10 min of 100nM BIM23120 exposure most of 
SSTR2 clusters colocalized with associated AP2 pits in FLNA 17-18 expressing cells. This degree 
of colocalization strongly decreased in FLNA 19-20 transfected cells, in the same condition of 
stimulation, thus suggesting a crucial scaffold role of FLNA in organizing the component of the 
endocytotic machinery (Fig. 11).  
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Figure 11.  CHO cells were transiently cotransfected with SNAP-tagged SSTR2 (green) and FLNA truncated fragments 
FLNA 17-18/19-20 (white, lower inset). After receptor  labeling, cells were treated with 100nM  BIM23120 for 10 min 
at 37°C, then fixed in PFA 4% and immunostained for AP-2 (magenta) before mounting on coverslips. The figure 
shows representative confocal sections of the plasma membranes. Arrows in the magnification indicate colocalization 
events (white) between SSTR2 cluster and AP-2 defined pits which are present in control FLNA 17-18 expressing cells, 
only. 
 
4.5 Interfering with SSTR2-FLNA interaction impairs SSTR2 internalization 
Giving our observations of FLNA regulating the SSTR2 early endocytosis steps, we attempted to 
evaluate the impact of the abolished FLNA-SSTR2 interaction on the overall SSTR2 internalization 
process after agonist stimulation. Subcellular distribution of SSTR2 was analyzed by confocal 
microscopy in CHO cells transiently cotransfected with SSTR2 and FLNA fragments, incubated 
with or without 100nM BIM23120 for 15, 30 and 60 min as shown in figure 12. Before receptor 
stimulation SSTR2 was exclusively confined to the plasma membrane in both FLNA mutants 
expressing cells. The time course stimulation experiments showed a robust receptor internalization 
in control cells, already appreciable after 15 min of receptor activation, whilst it resulted strongly 
impaired in the absence of FLNA-SSTR2 coupling.  
 
Figure 12.  Impact of disrupted FLNA-SSTR2 interaction on agonist-mediated SSTR2 internalization. CHO cells 
transiently overexpressing SNAP-tagged SSTR2 (green) and FLNA truncated mutants (white inset) FLNA 17-18 and 
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FLNA 19-20, upper and lower panel, respectively, were stained with 1µM Alexa647-BG dye and incubated with 
100nM BIM23120 for 0, 15, 30, and 60 min. DAPI was used to stain the nucleus. Fixed cells were analyzed by confocal 
microscopy. The figures show intracellular sections representative of receptor translocation from the plasma membrane 
to the interior compartment. In FLNA 17-18 expressing cells the receptor internalization rate increases through the time 
window considered, whereas it results significantly reduced in presence of FLNA 19-20, as demonstrated by the 
abundant presence of cell surface SSTR2 staining after 30 - 60 min of receptor stimulation. 
 
The quantitative analysis, performed by calculating the membrane to intracellular SSTR2 
fluorescence ratio (fR), reported that the lack of FLNA-SSTR2 interaction significantly reduced 
SSTR2 internalization rate at all the tested time points, as reported in the graph and table below 
(Fig. 13).  
 
 
Figure 13. Quantitative analysis of SSTR2 internalization rate. A) The quantitative analysis of SSTR2 
internalization from confocal images was performed by calculating the fR with NIH ImageJ program. For each group, at 
least 30 cells from three independent transfections were analyzed. B) Histograms showing the results of quantitative 
analysis of SSTR2 internalization from confocal images. For each group, at least 15 cells from three independent 
transfections were analyzed by calculating the fR with NIH ImageJ program. Mean ± SD values were used for the 
graph. **, P < 0.01, *** P < 0.001 vs FLNA 17-18 expressing cells; §, P < 0.05, §§, P < 0.01 vs respective basal.  
57 
 
To confirm this result we performed a biochemical assay of surface biotinylated proteins. 
Accordingly, we demonstrated that SSTR2 internalization occurring in cells transfected with FLNA 
17-18 was strongly reduced in cells expressing FLNA 19-20 (39,1% ± 11,6% internalization vs 
9,0% ± 3,4% in cells expressing FLNA 17-18 vs FLNA 19-20, respectively, P < 0.05 after 30 min of 
100nM BIM23120 incubation (Fig. 14). 
 
Figure 14. SSTR2 internalization determination by biotinylation assay. A representative biotinylation experiment is 
shown. CHO cells transiently transfected with FLNA 17-18 or FLNA 19-20 and wild-type SSTR2 were treated or not 
with 100nM BIM23120 for 30 min. Surface receptors were then biotinylated and cells were lysed. SSTR2 
immunoprecipitation was assessed by using an anti-SSTR2 antibody and immunoblotting was performed with an anti-
biotin antibody as described in material & methods. SSTR2 internalization is expressed as a percentage relative to basal, 
normalized to the total amount of receptor. The densitometrical analysis was performed by NIH ImageJ software for 
three independent experiments and the mean value ± SD was used for the graph. *, P < 0.05 FLNA 17-18 vs FLNA 19-
20 transfected cells; §§ = p<0.01 vs respective basal. 
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5. DISCUSSION 
 
The present research investigated the dynamics of SSTR2-FLNA interactions at the plasma 
membrane level, revealing a crucial active role of the cytoskeleton protein FLNA in spatially and 
temporally coordinating SSTR2 internalization.  
In an attempt to better understand the molecular determinants at the basis of the pharmacological 
resistance to SSA displayed by a subset of acromegalic patients, FLNA has been recently pointed 
out as a new modulator of the activity and stability of SSTR2 (Peverelli et al., 2014), which is the 
SSTR subtype mostly expressed at the surface of GH-secreting tumoral cells. However, compared 
with the large series of studies dealing with SSTR2 signaling, SSTR2 dynamics under resting 
conditions or after agonist activation are mostly unexplored in vivo, and to date, there are no 
evidence describing the behavior of SSTR2-FLNA interactions in living cells. Here, we used the 
single molecule live-cell imaging approach to visualize, in real time, the formation of FLNA-
SSTR2 complexes at the cell surface and study the impact of FLNA-SSTR2 binding on receptor 
mobility. Moreover, we investigated the FLNA linking role between SSTR2 and the cortical actin 
cytoskeleton and its involvement in SSTR2 agonist induced-endocytosis.  
Previous works demonstrated the efficiency of the strategy which combines single molecule TIRF-
M, and the direct labeling of the protein of interest with small organic fluorophores through 
SNAP/CLIP-tags, to perform dynamic studies (Keppler et al., 2003; Kasai et al., 2011; Calebiro et 
al., 2013). SNAP-tagged SSTR2 and CLIP-tagged FLNA were considered valuable tools for our 
investigations. In fact, SNAP-tagged receptor displayed the correct cell distribution  and maintained 
the ability to couple to the Gi/o signal transduction pathway, in terms of cAMP inhibition upon 
stimulation, as the wild type-receptor. CLIP-tagged FLNA showed the typical subcellular 
localization in stress fibers and colocalized with actin filaments, thus confirming that the insertion 
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of tags within the first hinge region of the FLNA monomer does not interfere with its actin binding 
properties (Planagumà et al., 2012). 
First, the analysis of receptor mobility revealed that SSTR2 freely diffuses at the plasma membrane 
in living cells. Moreover, the percentage of the mobile fraction is very high (>86%) under resting 
condition. This finding was completely in agreement with the fluorescence recovery after 
photobleaching (FRAP) results obtained with murine SST2a, in living hippocampal neurons 
(Lelouvier et al., 2008). The dynamic properties of SSTR2 are modulated by the agonist 
stimulation, as demonstrated by a significant increase in the immobile receptor fraction compared to 
the basal state. These data seem to indicate that normally only a minor population of SSTR2 might 
be associated with cytoskeleton anchoring proteins, whereas such interactions more often occur 
when the receptor is activated. This observation is true for other GPCRs such as the β-adrenergic 
receptor (Hall et al., 1998), whilst it does not seem the case of GABAB receptor, whose limited 
mobility is accelerated by the effect of GABA, likely due to a diminished binding with the cortical 
actin filaments (Calebiro et al., 2013). 
However, SSTR2 speed is not regulated by FLNA interaction. As shown by MSD analysis, the 
presence of the FLNA truncated mutant FLNA 19-20, which selectively prevents the endogenous 
FLNA binding to SSTR2, did not affect SSTR2 lateral diffusion in any condition. FLNA repeats 
19-20 are known to contain the SSTR2-binding region (Najib et al., 2012) and the overexpression 
of this FLNA fragment was recently successfully used to understand the impact of the abolished 
SSTR2-FLNA complex formation on receptor signaling and downregulation in GH-secreting cells 
(Peverelli et al., 2014). To note that this dominant negative approach was validated by another study 
with the purpose to avoid D2R-FLNA interaction (Lin et al., 2002). We excluded the hypothesis of 
a possible role of FLNA in the regulation of SSTR2 mobility by performing single-molecule 
experiments in A7 and M2 cell lines. According to our observation, high-resolution particle 
tracking showed no differences in the total mobility of Cav1–GFP vesicles over a time scale of 60 
seconds regardless of FLNA expression (Muriel et al., 2011). Nevertheless, the same TIRF-M 
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strategy was used to evaluate the diffusion of membrane associated vesicles, which resulted 
significantly decreased in cells with reduced FLNA (Sverdlov et al., 2009). 
Next, we analyzed the nature of SSTR2-FLNA interactions in living CHO cells transfected with 
single-molecule levels of SSTR2 and overexpressing FLNA-EGFP. Interestingly, dynamic and 
transient SSTR2-FLNA interactions observed under basal condition became more stable and long-
lasting upon 5-10 min of SSTR2 agonist exposure. Therefore, even though upon SSTR2 stimulation 
FLNA does not contribute to the enrichment of the immobile receptor fraction, it seems to act as 
scaffold platform where ligand-activated receptors preferentially stop, likely to initiate their 
signaling transduction, then followed by internalization. It is to be taken into account that these 
imaging data might be consistent with the immunoprecipitation results obtained by Najib and co-
workers, which illustrated an increase of FLNA recruitment to SSTR2 and MOR, upon ligand 
treatment, in BON and SH-SY5Y cells, respectively (Najib et al., 2012). 
Moreover, we demonstrated a key role of the cortical actin cytoskeleton in the 
compartimentalization of agonist-induced SSTR2-FLNA complexes. As recorded by our single 
molecule movie clips, long-lasting colocalizations between SSTR2 and FLNA single particles 
occurred along actin filaments at the cells surface of living CHO cells, under stimulation condition, 
only. The dynamics of these interactions may be ruled by the "membrane-skeleton fence model" 
previously proposed (Tsuji et al., 1988; Kusumi et al., 1993). This model describes a membrane-
associated cytoskeleton meshwork, also called membrane skeleton, as a physical barrier to the free 
diffusion of transmembrane proteins, which in turn confines their motion into defined 
compartments of the plasma membrane. The finely regulated dissociation-association equilibrium 
of the cytoskeleton continuously modulates the dynamic properties of the membrane skeleton, so 
that the space between the membrane and the skeleton may vary over time, giving the membrane 
proteins the chance to cross the barrier and reach specific domains within the cells surface.   
When overexpressed and stimulated for 5-10 min with the agonist, SSTR2 was observed to undergo 
cluster formation at the level of the plasma membrane, whereas it was widely distributed throughout 
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the cell surface in absence of stimuli. The receptor arrangement in clusters and their alignment 
along actin filaments were explored by confocal microscopy in presence of FLNA truncated 
mutants. Our observation showed that the disruption of SSTR2-FLNA interaction did not affect the 
SSTR2 organization in clusters. A similar finding has been reported for the chemokine (C-C motif) 
receptor 2B (CCR2B), where no difference in receptor clusterization was seen at the plasma surface 
of A7 and M2 cells, although a less reduction in the overall number of clusters upon ligand 
incubation was detected in FLNA depleted cells with respect to A7 cells, demonstrating the 
involvement of FLNA in regulating CCR2B endocytosis (Minsaas et al., 2010).  
Interestingly, we detected a remarkably reduced colocalization between SSTR2 clusters and actin 
filaments in presence of FLNA 19-20 compared to controls, showing that SSTR2 clusters cannot 
properly associate with the actin cytoskeleton without binding to FLNA.  
Furthermore, we demonstrated that like for other GPCRs and transmembrane proteins, FLNA 
interaction is required to initiate and sustain SSTR2 endocytosis (Lin et al., 2001; Cho et al., 2002; 
Onoprishvili et al., 2003; Seck et al., 2003; Zhang & Breitwieser, 2005; Minsaas et al., 2010; 
Muriel et al., 2011; Noam et al., 2014). SSTR2 endocytosis is known to be clathrin-coated pit 
mediated since it is inhibited by hypertonic sucrose, a common reagent used to block clathrin lattice 
formation (Koenig et al., 1998). Among the different proteins which cooperate to the formation of 
clathrin coated vesicles, the heterotetrameric adaptor complex AP-2 is one of the factor which 
identify nascent vesicles at the plasma membrane, since it disengages from sites of endocytosis 
seconds before intenalization (Rappaport et al., 2006). We performed AP-2 immunostaining to 
confirm that SSTR2 clusters were actually accumulated in nascent clathrin coated pits. We found a 
decrease in the colocalization rate between agonist-induced SSTR2 clusters and AP2-defined pits 
caused by the abolished SSTR2-FLNA interaction, strongly supporting a role for FLNA in 
mediating a cytoskeletal spatial orientation of coated pits. The actin cytoskeleton has been 
implicated in the maintenance of discrete sites of clathrin-coated pit assembling during receptor 
endocytosis. In addition, the observation that such pits tend to form repeatedly at defined regions 
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while excluding others has been attributable to the attachment of the pits to the membrane skeleton 
(Gaidarov et al., 1999; Bennet et al., 2001). Moreover, the actin network has been postulated to play 
both a structural role in clathrin-coated mediated endocytosis (CME), controlling the localization of 
endocytotic machinery on the plasma membrane, and a mechanical role, providing the force to drive 
invagination and translocation of the nascent vesicles into the cytoplasm (Qualmann et al., 2000; 
Qualmann & Kessels, 2002; Merrifield et al., 2002; Engqvist-Goldstein & Drubin, 2003). Here, we 
described FLNA as a potential molecular link between SSTR2 clusters/coated pits and actin. A 
similar clathrin/actin linker role has been previously characterized for other actin binding proteins 
such as the huntingtin interacting protein 1 related (Hip1R) (Bennet et al., 2001). 
The imaging and biochemical studies presented in the present work clearly demonstrate a crucial 
role for FLNA not only in the regulation of the early endocytotic events, but also in the overall 
SSTR2 internalization process. CHO cells displayed an agonist-induced SSTR2 internalization 
kinetic comparable to the ones already described in the literature (Koenig et al., 1997; Liu et al., 
2005; Liu et al., 2008; Cambiaghi et al., 2016), with about 70-80% of receptor completely localized 
in the intracellular compartment upon 30 min of agonist exposure, whereas it was strongly impaired 
when FLNA-SSTR2 association was prevented. The much slower internalization rate observed in 
FLNA-19-20 transfected cells might be due to an inefficient translocation of the nascent vesicles 
from the plasma membrane to the endosomes, a step which probably requires FLNA scaffold 
functions to properly orchestrate the endocytotic machinery without leaving some receptors at the 
cell surface. Indeed, a strong membrane staining of SSTR2 was visible at all the tested time points 
of stimulation in FLNA 19-20 expressing cells. Though, further experiments are required to 
examine the presence of possible alterations in the vesicles intracellular trafficking after the initial 
endocytosis, in cells lacking FLNA-SSTR2 interaction. However, it has to be mentioned that Najib 
and colleagues showed an accelerated SSTR2 internalization rate in A7 cells compared to M2 cells 
upon ligand treatment (Najib et al., 2012). The discrepancy between this data and our results might 
be due to cell-specific FLNA functions, and/or to the different approach used. In fact, the dominant 
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negative effect played by FLNA 19-20 in CHO cells selectively abrogates SSTR2-FLNA coupling 
without affecting the endogenous FLNA ability to cross-link and organize actin filaments into a 
dynamic cytoskeleton network, a property which is completely lost in M2 cells. 
Altogether the results presented in this thesis let us to speculate that, by tethering SSTR2 to actin 
filaments, FLNA may facilitate the formation of ligand-inducible complexes with interacting 
proteins that are necessary for the efficient endocytosis of the receptor into clathrin-coated vesicles. 
In this regard, it is possible that FLNA may coordinate the interaction between SSTR2 and β-
arrestins. It is well established that after the phosphorylation of Ser/Thr residues located at its C-tail, 
SSTR2 is able to recruit both β-arrestins, and together undergo internalization (Hipkin et al., 1997; 
Tulipano et al., 2004; Liu et al., 2005; Lehmann et al., 2014; Cambiaghi et al., 2016). Moreover, β-
arrestins binding site to FLNA involves repeat 22 of the FLNA monomer (Kim et al., 2005; Scott et 
al., 2006). A recent research focused on CCR2B and performed in melanoma cell lines, showed that 
in absence of FLNA β-arrestin 2 still binds to the receptor, but a delay in the formation of clathrin 
coated pits and in the receptor internalization occurs. Also in this case, the fate of the stimulated 
receptor seems to be dependent on FLNA association with components of the endocytotic 
machinery (Minsaas et al., 2010). As regards SSTR2, additional studies are needed to investigate 
the presence and eventually the biological meaning of SSTR2-FLNA-β-arrestins complexes at the 
plasma membrane. 
In conclusion, for the first time SSTR2-FLNA interactions were evaluated by means of a high 
spatio-temporal resolution technique, revealing the in vivo dynamics and the importance of this 
interaction for SSTR2 anchorage to the actin cortical cytoskeleton and internalization. Since a role 
for FLNA in the regulation of ligand-mediated SSTR2 signaling and downregulation has been 
already demonstrated in GH-secreting cells (Peverelli et al., 2014), it becomes relevant to continue 
elucidating the involvement of FLNA in the formation of compartmentalized domains at the plasma 
membrane, where SSTR2 are first assembled into functional units, and then subjected to 
endocytosis. Indeed, a deeper understanding of both these aspects may be useful to clarify the 
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molecular mechanisms by which the cells can modulate the amount of active receptors at their 
surface, thus determining a variable responsiveness to SSAs, with possible implications in the 
pharmacological resistance seen in the clinical management of acromegaly. 
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